CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsDavid Hung - Founder, President, ...

Can you get lung cancer without smoking? Yes. A leading oncologist explains the key differences in diagnosis, treatment, and ...

A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK fusion mutation and treat him with targeted therapy instead of chemotherapy.

Solihull mum-of-one Catherine Paul felt her body had 'betrayed' her after a cancer diagnosis - despite an organic diet and regular exercise ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...

The stake reduction represents a complete exit from Nuvalent, removing an allocation that was previously 13.8% of the fund’s reportable AUM in the prior quarter. Nuvalent is no longer in the portfolio ...

Detailed price information for Newamsterdam Pharma Company N.V. (NAMS-Q) from The Globe and Mail including charting and trades.

The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...